Noninvasive Prenatal Testing (NIPT): The Next Best Aneuploidy Screen?
|
|
- Dortha Cain
- 7 years ago
- Views:
Transcription
1 Noninvasive Prenatal Testing (NIPT): The Next Best Aneuploidy Screen? Becky Crosetto, MGC, LCGC Maureen Cantwell, MS, LCGC Regional Maternal-Fetal Medicine
2 If you currently do not know a lot about this topic, you are not alone Survey of OB providers (87% MDs & Dos; 11% NPs, RNs, & CNMs) Knowledge level not high 85% Sayers et al., 2011
3 Prevalence of Aneuploidy Overall (live birth, IUFD, termination): 1 in 228 (0.4%) 16% 5% 8% 5% 13% 53% Down syndrome Trisomy 18 Trisomy 13 45,X XXX, XXY, XYY Other Wellesley et al., 2012
4 Screening and invasive diagnostic testing for aneuploidy should be available to all women who present for prenatal care before 20 weeks of gestation regardless of maternal age.
5 Commonly Utilized Screens Test 1 st Trimester 2 nd Trimester Sequential Screen Serum Integrated Screen Quad Screen NT, PAPP-A, hcg PAPP-A AFP, hcg, ue3, DIA AFP, hcg, ue3, DIA AFP, hcg, ue3, DIA
6 Pregnancy Risk Screens Estimate Risks Based Largely on Phenotypic Factors hcg AFP ue3 Inhibin PAPP-A NT Verinata
7 Noninvasive Prenatal Tests Estimate Risks Based on DNA Verinata
8 Sources of Fetal DNA in Maternal Blood Cells (~1 fetal cell per 1 billion total cells) Persist between pregnancies Cell-free DNA (Not fetal per se) base pairs in length By 10 weeks gestation ~90% of total is maternal o primarily from apoptosis of blood cells ~10% is from the pregnancy o primarily from apoptosis of placental cells Half life < 20 minutes Undetectable < 2 hours postpartum Has been used for years for fetal RhD genotyping
9 Reduced risk to fetus (Available to all women) Goals of NIPT Reduced anxiety Reduced false positives Increased detection Verinata
10 Performance Comparison CVS Amnio Sequential NIPT Timing weeks 16 weeks weeks 10 weeks Procedure Risk Sensitivity Specificity Invasive Invasive Ultrasound and maternal blood 1% miscarriage >99% for aneuploidy >98% for aneuploidy (FPR <2%) 0.1% miscarriage >99% for aneuploidy >99% for aneuploidy (FPR <1%) None to pregnancy 90% for Down syndrome 95% for Down syndrome (FPR 5%) Maternal blood None to pregnancy >98% for Down syndrome >99% For Down syndrome (FPR <0.5%) Turn around <2 weeks <2 weeks <1 week <2 weeks
11 Sequencing Technology Explodes < 10 per 1 million base pairs by January 2012 Method Base pairs sequenced per run Time Sanger Tens of thousands < 1 day Next Generation Hundreds of billions (our genome is 3 billion bp in length) days
12 NIPT Timeline
13 2012 Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population KJ Nicholaides et al.
14 Companies Offering NIPT Launching early 2013
15 NIPT Technology Library Preparation Cluster Generation Massively Parallel Sequencing Mapping Reads Quantifying Reads Interpreting Data Reporting
16 Library Preparation PCR primers and indexes added to DNA sample Several libraries will be pooled (run in parallel), so each given unique index Pooled libraries loaded into flow cell cfdna PCR primer Index
17 Types of Libraries Shotgun sequencing (Sequenom, Verinata) All fragments are run (several million total) Targeted sequencing Fragments containing specific sequences are selected before run via PCR using specific primers Selection of nonpolymorphic loci (Ariosa) ~400 loci per chromosome of interest Each 56 base pairs in length Selection of polymorphic SNPs (Natera) SNP = single nucleotide polymorphism o characterized, common type of genetic variation among people > 10,000 total over all chromosomes of interest
18 NIPT Technology Library Preparation Cluster Generation Massively Parallel Sequencing Mapping Reads Quantifying Reads Interpreting Data Reporting
19 Cluster Generation Single strand library DNA hybridizes to complementary oligonucleotides anchored to the flow cell s surface PCR bridge amplification results in clusters of DNA Reverse strands are cleaved and washed away Sequencing primer is hybridized to the DNA Denature Bridge Amplification Denature Cleave Illumina
20 Massively Parallel Sequencing Clusters are sequenced simultaneously One by one, fluorescently-labeled reversible terminator nucleotides are incorporated and fluoresced by laser Each base (A, T, C, G) has its own color Each cycle is captured digitally Illumina
21 Factors Influencing Sequencing Depth of sequencing coverage Average number of times each base pair is sequenced GC content G-C nucleotide pairs held together by 3 hydrogen bonds and A-T pairs by two When GC content high or low, DNA forms hairpins and polymerase does not bind well In some types of data analysis a correction factor is needed % GC Content by Chromosome Natera
22 NIPT Technology Library Preparation Cluster Generation Massively Parallel Sequencing Mapping Reads Quantifying Reads Interpreting Data Reporting
23 Mapping Reads 1 read = 1 fragment of contiguous nucleotide sequence Chromosomal origin of each fragment is determined by comparison to genome map DNA of known origin
24 Quantifying Fragments (8%) (1.5% of total genome) X Y
25 cfdna Maternal + Fetal Reference Chromosome(s) If expected amount: disomy If extra amount: trisomy = Thousands of chromosome 21 cfdna fragments
26 ) Fetal Fraction (%) Fetal Fraction (%) Importance of Fetal Fraction Relatively constant 10 weeks gestation Norton et al., 2011 Maternal obesity lowers fraction 1 Likely due to apoptosis of adipose tissue and larger blood volume Correction factor or cut-off needed? Euploid Down syndrome Euploid Maternal weight (lbs) Palomaki et al., 2011
27 Trisomy increases total DNA by only a small amount Accurate analysis requires 4% (currently) Fetal fraction Fetal Karyotype Chromosome 21 DNA as % of total DNA Any (0-100%) euploid 1.5 0% trisomy % trisomy % (typical) trisomy % of our genome is chromosome 21 DNA When a pregnancy has trisomy 21 and the fetal fraction is 10%, the amount of chromosome 21 DNA increases to 1.6% of the total DNA: = (%maternal)(%chr21)(#chr21 to #expected) + (%fetal)(%chr21)(#chr21 to #expected) = (90%)(1.5%)(2/2) + (10%)(1.5%)(3/2) = = = 1.6%
28 NIPT Technology Library Preparation Cluster Generation Massively Parallel Sequencing Mapping Reads Quantifying Reads Interpreting Data Reporting
29 Normalizing Quantified Fragments Intra- & inter-run variation in the chromosomal distribution of reads can obscure aneuploidy Therefore, # reads mapping to chromosome of interest is normalized to # reads mapping to reference chromosomes # of standard deviations from the mean is calculated If reference chromosomes = all chromosomes: o Called Z-score o Correction factor for GC content needed If reference chromosomes = chromosomes with biochemical behaviors similar to chromosome of interest: o Called Normalized Chromosome Value (NCV) o If GC content similar, correction factor not needed
30 Normalized Chromosome Value (Verinata) Z-Score (Sequenom, Ariosa) Bianchi et al., 2012 Palomaki et al., 2011
31 Analyzing Allelic Distribution Maternal + fetal cfdna Buffer separates cells (virtually all maternal) from cfdna Maternal cellular DNA Targeted SNP sequencing Targeted SNP sequencing Multiple hypotheses are generated for each chromosome of interest, taking possible gamete crossover events into account Natera Algorithm subtracts out maternal allelic distribution (and paternal if available), taking possible crossovers into account, and selects result with highest significant likelihood Quantification of reads not needed Mapping not needed because location of SNPs known
32 Sponsor Sequenom Verinata Ariosa Natera Publication Palomaki et al., 2012, 2011 Bianchi et al., 2012 Norton et al., 2012 Zimmerman et al., 2012 Blinded nested casecontrol study Prospective blinded nested case-control study Prospective blinded cohort study Proof-of-principle study, algorithm blinded to karyotypes Eligibility High risk, 9-22 wks, singleton, undergoing invasive procedure High risk, 8-22 wks, singleton, undergoing invasive procedure High (primarily) and general risk, wks, singleton, undergoing invasive procedure Singleton, 9wks, aneuploids confirmed by invasive procedure Method Shotgun MPS (4-plex, 36-bp reads, 5 million reads) Shotgun MPS (6-plex, 36-bp reads, 2-14 million reads) Targeted MPS (oligonucleotides) (56-bp reads) Targeted MPS (SNPs) (10 million reads, 6.5 million mapping to targeted SNPs) Analyzed cohort 1,971, 286 aneuploids 532, >155 aneuploids 3,007, >119 aneuploids 145, 20 aneuploids # True positives T21: 209/212 T18: 59/59 T13: 11 /12 Sensitivity % (95% CI) Specificity % (95% CI) T21: 98.6% ( ) T18: 100% ( ) T13: 91.7% (61-99) T21: 99.8% ( ) T18: 99.7% ( ) T13: 99.0% ( ) T21: 89/89 T18: 35/36 T13: 11/14 45X: 15/16 T21: 100.0% ( ) T18: 97.2% ( ) T13: 78.6% ( ) 45X: 93.8% ( ) T21: 100.0% ( ) T18: 100.0% ( ) T13: 100.0% ( ) 45X: 99.8% ( ) T21: 81/81 T18: 37/38 T21: 100% ( ) T18: 97.4% ( ) T21: 99.97% ( ) T18: 99.93% ( ) T21: 11/11 T18: 3/3 T13: 2/2 45X: 2/2 XXY: 2/2 No call rate 0.8% 2.8% 0% 12.6% > 99% for T21, T18, T13, 45X, XXY > 99% for T21, T18, T13, 45X, XXY Failure rate 5.3% 3.0% 4.6% Majority of no calls
33 NIPT Technology Library Preparation Cluster Generation Massively Parallel Sequencing Mapping Reads Quantifying Reads Interpreting Data Reporting
34 Z-score / NCV Z-score / NCV Challenge of Threshold Results Unaffected Affected Verinata VS. Trisomy Diploid Dual Threshold Method (Verinata) Single Threshold Method (Sequenom)
35 Eligibility High risk High risk Method Shotgun MPS Shotgun MPS High and general risk Oligo targeted MPS? SNP targeted MPS Analysis Quantification, Z-score Quantification, NCV Quantification, Z-score Allelic distribution Report Positive (if Z-score >3) Negative (if Z-score <3) Aneuploidy Detected (if NCV >4) Aneuploidy Not Detected (if NCV <2.5) Aneuploidy Suspected (if NCV 2.5-4) High Risk >99% Low Risk <0.1% In Between?
36 Sample Lab Reports
37
38
39
40
41
42 Some Limitations Diagnostic testing, = Advanced screening Diagnostic testing is recommended following all positive results Chance pregnancy affected 50% Negative result does not ensure unaffected pregnancy Placental mosaicism (such as seen with CVS) Maternal mosaicism Unrecognized or vanishing twin Some screens not appropriate if egg donated Generating post-screen risks (continued )
43 Unaffected Affected Care must be taken not to generate unrealistic risks Risks only relevant in area of overlap May be reasonable to generate likelihood ratios in this area Not clear at this time whether post-test risk calculation is appropriate e.g. not yet determined whether NIPT behaves similarly in highrisk and general-risk populations
44 Ethical Considerations Informed consent for a complex test without fetal risk Just a tube of blood Will NIPT be lumped into other blood draws? Will ramifications be adequately presented by providers? Will ramifications be adequately considered by patients?
45 Future Directions Where will NIPT fit in? Replace or accompany serum screening? NT screening? Validation in the general population ACOG states NIPT should not be offered to general-risk patients at this time Validation in multiple gestations ACOG states NIPT should not be offered to patients with multiples at this time Determine whether feasible technology for detection of chromosomal mosaicism, subchromosomal anomalies (microdeletions and duplications)
46 Published Guidelines International Society for Prenatal Diagnosis (2011) With suitable genetic counseling MPS can be helpful for women who may have been determined to be high risk. Before routine MPS-based population screening for fetal Down syndrome is introduced additional trials are needed. This test is not fully diagnostic and therefore constitutes an advanced screening test. Accordingly, confirmation of MPS positive results through invasive testing would still be required.
47 NSGC currently supports NIPT as an option for patients whose pregnancies are considered to be at an increased risk for certain chromosome abnormalities. NSGC urges that NIPT/NIPD only be offered in the context of informed consent, education, and counseling by a qualified provider, such as a certified genetic counselor. Patients whose NIPT results are abnormal, or who have other factors suggestive of a chromosome abnormality, should receive genetic counseling and be given the option of standard confirmatory diagnostic testing. (2012)
48 Patients at increased risk of aneuploidy can be offered testing (AMA, associated u/s anomaly, prior affected pregnancy, positive risk screen, parent carries robertsonian translocation involving chromosome 13 or 21) Should not be part of routine prenatal laboratory assessment, but an informed patient choice after appropriate pretest counseling. Should not be offered to low-risk women or women with multiple gestations. If a fetal structural anomaly is identified on ultrasound, invasive prenatal diagnosis should be offered. A patient with a positive test result should be referred for genetic counseling and offered invasive prenatal diagnosis for confirmation of test results. Does not replace the accuracy and diagnostic precision of CVS or amniocentesis, which remain an option for women.
49 Thank you! Becky Crosetto, MGC Licensed & Certified Genetic Counselor Maureen Cantwell, MS Licensed & Certified Genetic Counselor Regional Maternal-Fetal Medicine
50 References American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine. Committee Opinion No. 545, December Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120: American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 88, December Invasive prenatal testing for aneuploidy. Obstet Gynecol Dec;110(6): PubMed PMID: Ashoor G, Syngelaki A, Wagner M, et al.. Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol Apr;206(4):322. PubMed PMID: Bianchi DW, Platt LD, Goldberg JD, et al.. MatErnal BLood IS Source to Accurately diagnose fetal aneuploidy (MELISSA) Study Group. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol May;119(5): PubMed PMID: Chiu RW, Akolekar R, Zheng YW, et al.. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ Jan 11;342:c7401. doi: /bmj.c7401. PubMed PMID: ; PubMed Central PMCID:PMC Chiu RW, Chan KC, Gao Y, et al.. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A Dec 23;105(51): Epub 2008 Dec 10. PubMed PMID: ; PubMed Central PMCID:PMC Eddleman KA, Malone FD, Sullivan L, et al.. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol Nov;108(5): PubMed PMID:
51 Ehrich M, Deciu C, Zwiefelhofer T, et al.. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol Mar;204(3):205.e1-11. Epub 2011 Feb 18. PubMed PMID: Fan HC, Blumenfeld YJ, Chitkara U, et al.. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A Oct 21;105(42): Epub 2008 Oct 6. PubMed PMID: ; PubMed Central PMCID: PMC Hahnemann JM, Vejerslev LO. Accuracy of cytogenetic findings on chorionic villus sampling (CVS)-- diagnostic consequences of CVS mosaicism and non-mosaic discrepancy in centres contributing to EUCROMIC Prenat Diagn Sep;17(9): Pubmed PMID: Lo YM, Tein MS, Lau TK, et al.. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet Apr;62(4): PubMed PMID: ; PubMed Central PMCID: PMC NSGC. Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis: the position of the National Society of Genetic Counselors NCHPEG and the National Society of Genetic Counselors (NSGC). Non-Invasive Prenatal Testing (NIPT) Factsheet Retrieved from Norton ME, Brar H, Weiss J, et al.. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol Aug;207(2):137.e1-8. doi: /j.ajog Epub 2012 Jun 1. PubMed PMID: Palomaki GE, Deciu C, Kloza EM, et al.. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med Mar;14(3): doi: /gim Epub 2012 Feb 2. PubMed PMID:
52 Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al.. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med Nov;13(11): PubMed PMID: Palomaki GE, Steinort K, Knight GJ, Haddow JE. Comparing three screening strategies for combining first- and second-trimester Down syndrome markers. Obstet Gynecol Feb;107(2 Pt 1): PubMed PMID: Sayres LC, Allyse M, Norton ME, Cho MK. Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation. Prenat Diagn Nov;31(11): doi: /pd Epub 2011 Jul 27. PubMed PMID: Sehnert AJ, Rhees B, Comstock D, et al.. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem Jul;57(7): Epub 2011 Apr 25. PubMed PMID: Sparks AB, Wang ET, Struble CA, et al.. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn Jan;32(1):3-9. doi: /pd Epub 2012 Jan 6. PubMed PMID: Sparks AB, Struble CA, Wang ET, et al... Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol Apr;206(4):319.e1-9. Epub 2012 Jan 26. PubMed PMID: Wellesley D, Dolk H, Boyd PA, et al.. Rare chromosome abnormalities, prevalence and prenatal diagnosis rates from population-based congenital anomaly registers in Europe. Eur J Hum Genet May;20(5): doi: /ejhg Epub 2012 Jan 11. PubMed PMID: Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Large-Scale Genome Sequencing Program Available at: Accessed 11/20/2012. Zimmermann B, Hill M, Gemelos G, et al.. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012 Oct 32:1-9 doi: /pd.3993 PubMed PMID:
Non-Invasive Prenatal Testing (NIPT) Factsheet
Introduction NIPT, which analyzes cell-free fetal DNA circulating in maternal blood, is a new option in the prenatal screening and testing paradigm for trisomy 21 and a few other fetal chromosomal aneuploidies.
More informationSequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA
Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013
More informationClinical Studies Abstract Booklet
Clinical Studies Abstract Booklet The Harmony Prenatal Test is a non-invasive prenatal test (NIPT) that assesses the risk of trisomies by analyzing cell-free DNA (cfdna) in maternal blood. Since January
More informationyour questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.
your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. Accurate answers about your baby s health simply, safely, sooner. What is the verifi Prenatal
More informationCurrent Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma
No. 287, February 2013 Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma This committee opinion has been prepared by
More informationNoninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA
Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
More informationcfdna in maternal plasma obtained from a population undergoing routine screening at 11-13 weeks gestation.
Reports of Major Impact www.ajog.org Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population Kypros H. Nicolaides, MD; Argyro Syngelaki, RM; Ghalia Ashoor, MD;
More informationNoninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions
More informationIn most developed countries, prenatal screening
Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing Diana W. Bianchi, MD, Lawrence D. Platt, MD, James D. Goldberg, MD, Alfred Z. Abuhamad, MD, Amy J. Sehnert, MD, and Richard P. Rava,
More informationCOMMITTEE OPINION. Cell-free DNA Screening for Fetal Aneuploidy
The American College of Obstetricians and Gynecologists WOMEN S HEALTH CARE PHYSICIANS (Published Electronically Ahead of Print on June 26, 2015) COMMITTEE OPINION Number 640 September 2015 (This Committee
More informationTrisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method
Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method Ghalia ASHOOR 1, Argyro SYNGELAKI 1, Eric WANG 2, Craig STRUBLE 2, Arnold OLIPHANT 2,
More informationA test your patients can trust.
A test your patients can trust. A simple, safe, and accurate non-invasive prenatal test for early risk assessment of Down syndrome and other conditions. informaseq Prenatal Test Simple, safe, and accurate
More informationNon-invasive prenatal detection of chromosome aneuploidies using next generation sequencing: First steps towards clinical application
Non-invasive prenatal detection of chromosome aneuploidies using next generation sequencing: First steps towards clinical application PD Dr. rer. nat. Markus Stumm Zentrum für Pränataldiagnostik Kudamm-199
More informationA test your patients can trust. A company you know and trust.
A test your patients can trust. A company you know and trust. informaseq Prenatal Test an advanced, non-invasive, prenatal screening for T21, T18, and T13 chromosomal aneuploidies using next generation
More informationNew Prenatal Tests for Down Syndrome: Brian G. Skotko, MD, MPP Co-Director, Down Syndrome Program Massachusetts General Hospital
New Prenatal Tests for Down Syndrome: International Updates and What This All Means for Your Family Brian G. Skotko, MD, MPP Co-Director, Down Syndrome Program Massachusetts General Hospital Band of Angels
More informationComplimentary and personal copy for
Complimentary and personal copy for www.thieme.com Publishing House and Copyright: 2015 by Georg Thieme Verlag KG Rüdigerstraße 14 70469 Stuttgart ISSN Any further use only by permission of the Publishing
More informationSelective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy
DOI: 10.1002/pd.2922 ORIGINAL ARTICLE Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy Andrew B. Sparks 1, Eric T. Wang 1, Craig A. Struble 1, Wade Barrett 1, Renee
More informationImplementation of maternal blood cell-free DNA testing in early screening for aneuploidies
Ultrasound Obstet Gynecol 2013; 42: 34 40 Published online 7 June 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.12504 Implementation of maternal blood cell-free DNA testing in
More informationOptimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal Blood
Clinical Chemistry 57:7 1042 1049 (2011) Molecular Diagnostics and Genetics Optimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal
More informationFirst Trimester Screening for Down Syndrome
First Trimester Screening for Down Syndrome What is first trimester risk assessment for Down syndrome? First trimester screening for Down syndrome, also known as nuchal translucency screening, is a test
More informationNon-invasive Prenatal Testing for Chromosomal Abnormality using Maternal Plasma DNA
Non-invasive Prenatal Testing for Chromosomal Abnormality using Maternal Plasma DNA Scientific Impact Paper No. 15 March 2014 Non-invasive Prenatal Testing for Chromosomal Abnormality using Maternal Plasma
More informationFetal Fraction Estimate in Twin Pregnancies Using Directed Cell-Free DNA Analysis
Original Paper Received: August 22, 2013 Accepted after revision: September 17, 2013 Published online: December 7, 2013 Pregnancies Using Directed Cell-Free DNA Analysis Craig A. Struble a Argyro Syngelaki
More informationPosition Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis, April 2013
Position Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis, April 2013 Peter Benn (Chair), Antoni Borell, Rossa Chiu, Howard Cuckle,
More informationMaternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester
PRENATAL DIAGNOSIS Prenat Diagn 2000; 20: 390±394. Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester Kevin Spencer 1 *, Natasha Tul 2 and Kypros H. Nicolaides 2
More informationLEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD
LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD 2 Outline Genetics 101: Basic Concepts and Myth Busting Inheritance Patterns
More informationThe first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands
FVV in ObGyn, 2014, 6 (1): 7-12 Preliminary report The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands P.J. Willems 1, H. Dierickx 1, ES. Vandenakker
More informationMASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA
Scuola di specializzazione in Genetica Medica Journal Club 14 gennaio 2014 MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA Bianchi, Diana W. MD; Prosen,
More informationCytogenetic and Molecular Diagnosis in Gestational Disorders
Cytogenetic and Molecular Diagnosis in Gestational Disorders Katherine Geiersbach, M.D. Assistant Professor, Department of Pathology University of Utah School of Medicine Medical Director, Cytogenetics
More informationConsent to Perform Preimplantation Genetic Screening (PGS) using. Comparative Genomic Hybridization (acgh) or Next Generation Sequencing (NGS)
Consent to Perform Preimplantation Genetic Screening (PGS) using Array Comparative Genomic Hybridization (acgh ) or Next Generation Sequencing (NGS) Purpose The purpose of Preimplantation Genetic Screening
More informationORIGINAL ARTICLE. Supporting information may be found in the online version of this article.
DOI: 10.1002/pd.4002 ORIGINAL ARTICLE Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11 105 pregnancies with mixed risk factors
More informationCHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
More informationExecutive summary. Current prenatal screening
Executive summary Health Council of the Netherlands. NIPT: dynamics and ethics of prenatal screening. The Hague: Health Council of the Netherlands, 2013; publication no. 2013/34. In recent years, new tests
More informationfi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас...
АВАВАКдлАмА дла длама АсАядлАмА АВА АсдлАя & MАядлдлАмАК TА. 4, T. 2, АВ. 113-118, 2005 fi АУ : Аяapplefi. fiapple АсА» Ас Ам, длappleapple Ас..., Ая: Аяapplefi. fiapple, АВАУ Ас, АсА» Ас Ам длappleapple
More informationResearch. Currently, the most effective and
Research GENETICS Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18 Mary E. Norton, MD; Herb Brar, MD;
More informationChromosomes, Karyotyping, and Abnormalities (Learning Objectives) Learn the components and parts of a metaphase chromosome.
Chromosomes, Karyotyping, and Abnormalities (Learning Objectives) Learn the components and parts of a metaphase chromosome. Define the terms karyotype, autosomal and sex chromosomes. Explain how many of
More informationPrenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy This statement has been
More informationThe California Prenatal Screening Program
The California Prenatal Screening Program Provider ook netic Disease Screening Program Quad Marker Screening Serum Integrated Screening Full Integrated Screening TABLE OF CONTENTS WELCOME to the California
More informationThe California Prenatal Screening Program
The California Prenatal Screening Program Quad Marker Screening One blood specimen drawn at 15 weeks - 20 weeks of pregnancy (second trimester) Serum Integrated Screening Prenatal Patient Booklet - English
More informationThe National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report
0 The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report Joan K Morris, Elizabeth De Souza December 2009 National Down Syndrome Cytogenetic Register Queen Mary University
More informationObstetrical Ultrasound and Prenatal Diagnostic Center
Obstetrical Ultrasound and Prenatal Diagnostic Center Prenatal Diagnosis: Options and Opportunities Learn about various screening options including Early Risk Assessment (ERA), now available to women of
More informationUser guide for referring samples to the IBGRL Molecular Diagnostics Laboratory
International Blood Group Reference Laboratory (IBGRL) IBGRL provides specialist diagnostic services to NHS Blood and Transplant. The Molecular Diagnostics department is a CPA accredited laboratory and
More informationNational Down Syndrome Society
National Down Syndrome Society The national advocate for the value, acceptance and inclusion of people with Down syndrome What is Down Syndrome? Down syndrome is the most commonly occurring chromosomal
More informationREI Pearls: Pitfalls of Genetic Testing in Miscarriage
The Skinny: Genetic testing of miscarriage tissue is controversial and some people question if testing is helpful or not. This summary will: 1) outline the arguments for and against genetic testing; 2)
More informationPreimplantation Genetic Diagnosis (PGD) in Western Australia
Preimplantation Genetic Diagnosis (PGD) in Western Australia Human somatic cells have 46 chromosomes each, made up of the 23 chromosomes provided by the egg and the sperm cell from each parent. Each chromosome
More informationClinical Policy Title: Home uterine activity monitoring
Clinical Policy Title: Home uterine activity monitoring Clinical Policy Number: 12.01.01 Effective Date: August 19, 2015 Initial Review Date: July 17, 2013 Most Recent Review Date: July 15, 2015 Next Review
More informationGenetics and Pregnancy Loss
Genetics and Pregnancy Loss Dorothy Warburton Genetics and Development (in Pediatrics) Columbia University, New York Estimates of Pregnancy Loss from Conception 1000 fertilized eggs (27% are lost) 728
More informationChapter 9 Diagnostic testing for trisomy 18
Chapter 9 Diagnostic testing for trisomy 18 9.1 Diagnostic procedures: amniocentesis Introduction: An amniocentesis procedure involves the use of a small gauge needle inserted through the woman s abdomen
More informationOverview of Genetic Testing and Screening
Integrating Genetics into Your Practice Webinar Series Overview of Genetic Testing and Screening Genetic testing is an important tool in the screening and diagnosis of many conditions. New technology is
More informationThe following chapter is called "Preimplantation Genetic Diagnosis (PGD)".
Slide 1 Welcome to chapter 9. The following chapter is called "Preimplantation Genetic Diagnosis (PGD)". The author is Dr. Maria Lalioti. Slide 2 The learning objectives of this chapter are: To learn the
More informationPrenatal screening and diagnostic tests
Prenatal screening and diagnostic tests Contents Introduction 3 First trimester routine tests in the mother 3 Testing for health conditions in the baby 4 Why would you have a prenatal test? 6 What are
More informationGenetic Counseling: A Profession in the Making. Jessica Hooks, MS Genetic Counselor University of South Carolina
Genetic Counseling: A Profession in the Making Jessica Hooks, MS Genetic Counselor University of South Carolina Definition the process of helping people understand and adapt to the medical, psychological
More informationEach person normally has 23 pairs of chromosomes, or 46 in all. We inherit one chromosome per pair from our mother and one from our father.
AP Psychology 2.2 Behavioral Genetics Article Chromosomal Abnormalities About 1 in 150 babies is born with a chromosomal abnormality (1, 2). These are caused by errors in the number or structure of chromosomes.
More informationAND GENETIC TESTING FOR ALL... THE COMING REVOLUTION IN NON-INVASIVE PRENATAL GENETIC TESTING
AND GENETIC TESTING FOR ALL... THE COMING REVOLUTION IN NON-INVASIVE PRENATAL GENETIC TESTING Jaime S. King* For thousands of years, expecting parents have daydreamed of being able to know about their
More informationThe 11 13 +6 weeks scan
The 11 13 +6 weeks scan Kypros H. Nicolaides The 11 13 +6 weeks scan Fetal Medicine Foundation, London 2004 Dedication to Herodotos & Despina Contents Introduction 1. First trimester diagnosis of chromosomal
More information2. True or False? The sequence of nucleotides in the human genome is 90.9% identical from one person to the next. False (it s 99.
1. True or False? A typical chromosome can contain several hundred to several thousand genes, arranged in linear order along the DNA molecule present in the chromosome. True 2. True or False? The sequence
More informationThe genetic screening of preimplantation embryos by comparative genomic hybridisation
Vol. 11, Suppl. 3 51 The genetic screening of preimplantation embryos by comparative genomic hybridisation Maria V Traversa 1, James Marshall, Steven McArthur, Don Leigh Genea, Sydney, Australia Received:
More informationBasic Human Genetics: Reproductive Health and Chromosome Abnormalities
Basic Human Genetics: Reproductive Health and Chromosome Abnormalities Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland Training Course in Sexual and
More informationIBGRL, NHSBT, Bristol
IBGRL, NHSBT, Bristol Valuable to know D type of fetus Fetus D-positive: at risk pregnancy should be managed appropriately Fetus D-negative: not at risk no need for intervention RHD RHCE RHD* D 37 bp
More informationGenetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy
Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy Testing and pregnancy GP s role 3 Counselling before and during pregnancy 3 Collecting the family history
More informationSingle Nucleotide Polymorphisms (SNPs)
Single Nucleotide Polymorphisms (SNPs) Additional Markers 13 core STR loci Obtain further information from additional markers: Y STRs Separating male samples Mitochondrial DNA Working with extremely degraded
More informationPreimplantation Genetic Diagnosis (PGD) for Fanconi Anemia and HLA matching
Preimplantation Genetic Diagnosis (PGD) for Fanconi Anemia and HLA matching Andria G. Besser, BEd, MS, CGC Licensed Genetic Counselor Reproductive Genetics Institute Chicago, IL Outline PGD overview In
More informationFluorescence in situ hybridisation (FISH)
Fluorescence in situ hybridisation (FISH) rarechromo.org Fluorescence in situ hybridization (FISH) Chromosomes Chromosomes are structures that contain the genetic information (DNA) that tells the body
More informationRECURRENT PREGNANCY LOSS DR.RAJALAKSHMI SRINIVASAN SPECIALIST GYNECOLOGIST ZULEKHA HOSPITAL DUBAI
RECURRENT PREGNANCY LOSS DR.RAJALAKSHMI SRINIVASAN SPECIALIST GYNECOLOGIST ZULEKHA HOSPITAL DUBAI RECURRENT PREGNANCY LOSS -RM Clinically recognized consecutive or non consecutive pregnancy losses before
More informationInvasive Prenatal (Fetal) Diagnostic Testing
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Invasive Prenatal (Fetal) Diagnostic Testing Number 12.04.116
More informationMitochondrial DNA Analysis
Mitochondrial DNA Analysis Lineage Markers Lineage markers are passed down from generation to generation without changing Except for rare mutation events They can help determine the lineage (family tree)
More informationThe correct answer is c A. Answer a is incorrect. The white-eye gene must be recessive since heterozygous females have red eyes.
1. Why is the white-eye phenotype always observed in males carrying the white-eye allele? a. Because the trait is dominant b. Because the trait is recessive c. Because the allele is located on the X chromosome
More informationRapid Aneuploidy and CNV Detection in Single Cells using the MiSeq System
i Technical Note: Reproductive Health Rapid Aneuploidy and CNV Detection in Single Cells using the MiSeq System Comparison between data generated from single cells using 24sure array-based screening and
More informationValidation and Replication
Validation and Replication Overview Definitions of validation and replication Difficulties and limitations Working examples from our group and others Why? False positive results still occur. even after
More informationNoninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing
Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing Eric Z. Chen 1,2, Rossa W. K. Chiu 1,2, Hao Sun 1,2, Ranjit Akolekar 4, K. C. Allen Chan 1,2, Tak Y.
More informationWhat Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives
What Is Genetic Counseling? Helping individuals and families understand how genetics affects their health and lives What does the career involve? Explore family histories to identify risks Reducing risks
More informationPrenatal Care Screening and Testing Guideline
Prenatal Care Screening and Testing Guideline Major Changes as of October 2013 2 Visit Schedule 2 Initial Visit 3 Second Trimester Visits (14 28 Weeks) 11 Third Trimester Visits (28 41 Weeks) 12 Postpartum
More informationPrenatal Testing Special tests for your baby during pregnancy
English April 2006 [OTH-7750] There are a number of different prenatal (before birth) tests to check the development of your baby. Each test has advantages and disadvantages. This information is for people
More informationNeural tube defects: open spina bifida (also called spina bifida cystica)
Screening Programmes Fetal Anomaly Neural tube defects: open spina bifida (also called spina bifida cystica) Information for health professionals Publication date: April 2012 Review date: April 2013 Version
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More information3D Ultrasound. Outline. What is 3D US? Volume Sonography. 3D Ultrasound in Obstetrics: Current Modalities & Future Potential. Alfred Abuhamad, M.D.
in Obstetrics: Current Modalities & Future Potential Outline What is 3D US? What are obvious advantages of 3D US? What is the future of 3D US? Alfred Abuhamad, M.D. Eastern Virginia Medical School 2D US
More informationA Guide to Prenatal Genetic Testing
Patient Education Page 29 A Guide to Prenatal Genetic Testing This section describes prenatal tests that give information about your baby s health. It is your choice whether or not to have these tests
More informationFirst- and Second-Trimester Evaluation of Risk for Down Syndrome
Original Research First- and Second-Trimester Evaluation of Risk for Down Syndrome Robert H. Ball, MD, Aaron B. Caughey, MD, MPP, Fergal D. Malone, MD, David A. Nyberg, MD, Christine H. Comstock, MD, George
More informationPROFESSIONAL GUIDELINES FOR CLINICAL CYTOGENETICS AND CLINICAL MOLECULAR GENETICS
PROFESSIONAL GUIDELINES FOR CLINICAL CYTOGENETICS AND CLINICAL MOLECULAR GENETICS QF-PCR FOR THE DIAGNOSIS OF ANEUPLOIDY BEST PRACTICE GUIDELINES (2012) v3.01 January 2012 Registered as a specially authorised
More informationClinical Policy Title: Array comparative genomic hybridization testing
Clinical Policy Title: Array comparative genomic hybridization testing Clinical Policy Number: 02.01.03 Effective Date: Sept 1, 2015 Initial Review Date: May 13, 2013 Most Recent Review Date: August 19,
More informationSequencing and microarrays for genome analysis: complementary rather than competing?
Sequencing and microarrays for genome analysis: complementary rather than competing? Simon Hughes, Richard Capper, Sandra Lam and Nicole Sparkes Introduction The human genome is comprised of more than
More informationScreening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free β-hcg and PAPP-A at 11 + 0to13+ 6 weeks
Ultrasound Obstet Gynecol 2006; 27: 151 155 Published online 30 December 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.2699 Screening for trisomy 21 by fetal tricuspid regurgitation,
More informationInformation leaflet. Centrum voor Medische Genetica. Version 1/20150504 Design by Ben Caljon, UZ Brussel. Universitair Ziekenhuis Brussel
Information on genome-wide genetic testing Array Comparative Genomic Hybridization (array CGH) Single Nucleotide Polymorphism array (SNP array) Massive Parallel Sequencing (MPS) Version 120150504 Design
More informationBACKGROUND PAPER. Non-Invasive Prenatal Testing (NIPT) Identifying key clinical, ethical, social, legal and policy issues
BACKGROUND PAPER Non-Invasive Prenatal Testing (NIPT) Identifying key clinical, ethical, social, legal and policy issues Professor Vardit Ravitsky, University of Montreal, Canada 1 November 2015 Note The
More informationAnalytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers
DOI: 10.1002/pd.4019 ORIGINAL ARTICLE Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers Kevin Spencer* and Nicholas J. Cowans
More informationEffect of incorrect gestational dating on Down s syndrome and neural tube risk assessment
Original Article Ann Clin Biochem 2001; 38: 230±234 Effect of incorrect gestational dating on Down s syndrome and neural tube risk assessment S N Millner From the Department of Pathology, University of
More informationOBSTETRICAL POLICY. Page
OBSTETRICAL POLICY REIMBURSEMENT POLICY Policy Number: ADMINISTRATIVE 200.14 T0 Effective Date: April 1, 2016 Table of Contents APPLICABLE LINES OF BUSINESS/PRODUCTS... APPLICATION... OVERVIEW... REIMBURSEMENT
More informationTrisomy 13 (also called Patau s syndrome or T13)
Screening Programmes Fetal Anomaly Trisomy 13 (also called Patau s syndrome or T13) Information for parents Publication date: April 2012 Review date: April 2013 Version 2 117 Information sheet to help
More informationPrenatal Screening for Fetal Aneuploidy in Singleton Pregnancies
No. 261 (Replaces No. 187, February 2007) Prenatal Screening for Fetal Aneuploidy in Singleton Pregnancies This clinical practice guideline has been prepared by the Genetics Committee of the Society of
More informationGene Mapping Techniques
Gene Mapping Techniques OBJECTIVES By the end of this session the student should be able to: Define genetic linkage and recombinant frequency State how genetic distance may be estimated State how restriction
More informationPrediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in Cases of Habitual Abortions
Prediction of Pregnancy Outcome Using HCG, CA125 and Progesterone in * (MBChB, FICMS, CABOG) **Sawsan Talib Salman (MBChB, FICMS, CABOG) ***Huda Khaleel Ibrahim (MBChB) Abstract Background: - Although
More informationDisclosure. Objectives 2/21/2016
Recurrent Pregnancy Loss: The myths, the controversies and the evidence Mamie McLean, MD Assistant Professor Reproductive Endocrinology and Infertility University of Alabama at Birmingham Disclosure I
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationData Analysis for Ion Torrent Sequencing
IFU022 v140202 Research Use Only Instructions For Use Part III Data Analysis for Ion Torrent Sequencing MANUFACTURER: Multiplicom N.V. Galileilaan 18 2845 Niel Belgium Revision date: August 21, 2014 Page
More informationGene Therapy and Genetic Counseling. Chapter 20
Gene Therapy and Genetic Counseling Chapter 20 What is Gene Therapy? Treating a disease by replacing, manipulating or supplementing a gene The act of changing an individual s DNA sequence to fix a non-functional
More informationIllumina TruSeq DNA Adapters De-Mystified James Schiemer
1 of 5 Illumina TruSeq DNA Adapters De-Mystified James Schiemer The key to sequencing random fragments of DNA is by the addition of short nucleotide sequences which allow any DNA fragment to: 1) Bind to
More informationSonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation
American Journal of Obstetrics and Gynecology (2006) 194, 397 401 www.ajog.org Sonographic screening for trisomy 13 at 11 to 13 D6 weeks of gestation Aris T. Papageorghiou, MD, a Kyriaki Avgidou, MD, a
More information1. PRENATAL DIAGNOSIS OF CHROMOSOMAL DISORDERS - molecular aspects
1. PRENATAL DIAGNOSIS OF CHROMOSOMAL DISORDERS - molecular aspects Ana Stavljenić-Rukavina Zagreb University School of Medicine, Croatia The standard measures for population health outcomes is based on
More information4.2 Meiosis. Meiosis is a reduction division. Assessment statements. The process of meiosis
4.2 Meiosis Assessment statements State that meiosis is a reduction division of a diploid nucleus to form haploid nuclei. Define homologous chromosomes. Outline the process of meiosis, including pairing
More informationjournal of medicine The new england First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome abstract
The new england journal of medicine established in 1812 november 10, 2005 vol. 353 no. 19 First-Trimester or Second-Trimester Screening, or Both, for Down s Syndrome Fergal D. Malone, M.D., Jacob A. Canick,
More information